User profiles for "author:Paul Bird"

Paul W Bird

Clinical Scientist, University Hospitals of Leicester NHS Trust
Verified email at uhl-tr.nhs.uk
Cited by 3442

OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring …

M Østergaard, C Peterfy, P Conaghan… - The Journal of …, 2003 - jrheum.org
This article describes the 2002 OMERACT rheumatoid arthritis magnetic resonance image
scoring system (RAMRIS) for evaluation of inflammatory and destructive changes in RA …

[HTML][HTML] Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort …

KA Twohig, T Nyberg, A Zaidi, S Thelwall… - The Lancet Infectious …, 2022 - thelancet.com
Summary Background The SARS-CoV-2 delta (B. 1.617. 2) variant was first detected in
England in March, 2021. It has since rapidly become the predominant lineage, owing to high …

[HTML][HTML] Prevention and treatment of infectious diseases in migrants in Europe in the era of universal health coverage

RF Baggaley, D Zenner, P Bird, S Hargreaves… - The Lancet Public …, 2022 - thelancet.com
Some subpopulations of migrants to Europe are generally healthier than the population of
the country of settlement, but are at increased risk of key infectious diseases, including …

OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module.

F McQueen, M Lassere, J Edmonds… - The Journal of …, 2003 - jrheum.org
Magnetic resonance image (MRI) scanning is a new method for imaging and quantifying
joint inflammation and damage in rheumatoid arthritis (RA). Over the past 4 years, the …

[PDF][PDF] Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

E Volz, V Hill, JT McCrone, A Price, D Jorgensen… - Cell, 2021 - cell.com
Global dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G
are suggestive of a selective advantage but may also be due to a random founder effect. We …

[HTML][HTML] Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study

MS Graham, CH Sudre, A May, M Antonelli… - The Lancet Public …, 2021 - thelancet.com
Summary Background The SARS-CoV-2 variant B. 1.1. 7 was first identified in December,
2020, in England. We aimed to investigate whether increases in the proportion of infections …

Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two‐year prospective study (the DAMAGE study cohort)

BW Kirkham, MN Lassere, JP Edmonds… - Arthritis & …, 2006 - Wiley Online Library
Objective The primary aim of this prospective 2‐year study was to explain the wide variability
in joint damage progression in patients with rheumatoid arthritis (RA) from measures of …

Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial

W Clark, P Bird, P Gonski, TH Diamond, P Smerdely… - The Lancet, 2016 - thelancet.com
Background We hypothesised that vertebroplasty provides effective analgesia for patients
with poorly controlled pain and osteoporotic spinal fractures of less than 6 weeks' duration …

Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis

A Deodhar, LS Gensler, J Sieper, M Clark… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐
controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included …

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

CJ Edwards, FJ Blanco, J Crowley… - Annals of the …, 2016 - ard.bmj.com
Objective To evaluate apremilast treatment in patients with active psoriatic arthritis, including
current skin involvement, despite prior therapy with conventional disease-modifying …